ANVS

Annovis Bio, Inc. (ANVS) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. Annovis Bio is a late-stage clinical drug platform company focused on neurodegeneration, specifically Alzheimer's disease (AD) and Parkinson's disease (PD). The company's lead product candidate, buntanetap, is an oral small molecule designed to inhibit the translation of multiple neurotoxic proteins. The company has no commercial revenue and is currently conducting pivotal Phase 3 trials.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses for the nine months ended September 30, 2025, were flat compared to the prior year ($19.99M vs. $19.96M). However, the composition shifted significantly:
  • R&D Expenses: Increased by $1.47 million YTD, driven by costs associated with the AD 6-month trial and bioanalytical work.
  • G&A Expenses: Decreased by $1.44 million YTD, primarily due to reduced stock-based compensation and lower stock listing fees.
• Other Income/Expense: The company recognized a gain of $0.44 million from the change in fair value of warrants for the nine months ended September 30, 2025, compared to a gain of $2.90 million in the prior year. This reduction is attributed to lower stock price volatility in 2025 compared to 2024.
• Financing Costs: Other financing costs were $0 in 2025, compared to $1.87 million in 2024, as the Equity Line of Credit (ELOC) facility was exhausted in 2024.
• Cash Position: Cash and cash equivalents increased from $10.55 million at year-end 2024 to $15.29 million at September 30, 2025, following a $19.3 million net proceeds registered direct offering in February 2025 and ATM sales.

Guidance, Outlook, and Risks

• Going Concern: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for one year following the filing date. Current cash is not sufficient to fund operations through that period without additional capital.
• Clinical Progress:
  • Alzheimer's Disease: The pivotal Phase 3 ANVS-25001 trial (6-month symptomatic efficacy + 12-month disease-modifying extension) was initiated in February 2025. The company aims to file an NDA potentially within one year of the 6-month period initiation.
  • Parkinson's Disease: The Phase 3 study was completed in December 2023. Topline data released in July 2024 showed improvements in specific subgroups and halted cognitive loss in the intent-to-treat population. An open-label extension study is ongoing.
• Capital Needs: The company expects to incur losses for the foreseeable future and will need to raise substantial additional capital to complete development and commercialization. Plans include public/private equity offerings, debt, or collaborations.
• Subsequent Events: Following the quarter end, the company raised an additional $10.1 million through October 2025 via ATM sales and two registered direct offerings (October 10 and October 26).

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $15.3 million cash balance against the burn rate of ~$16.7 million per nine months, considering the "substantial doubt" disclosure.
• Financing Dilution: Review the terms of the October 2025 registered direct offerings (priced at $1.50 and $2.05) and the impact on existing shareholders.
• Clinical Milestones: Monitor the enrollment and interim data release for the ANVS-25001 Phase 3 AD trial, which is critical for future NDA filing.
• Warrant Liability: Track the fair value of the remaining Canaccord Warrants (liability classified), which can cause non-cash volatility in net income.
• Regulatory Path: Confirm the FDA's stance on the dual NDA strategy (short-term symptomatic vs. long-term disease-modifying) for buntanetap.